Armin Lahm
Rome, 00153, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody.
Journal: Cancers
Published: December 08, 2025
Activity of Azole and Non-Azole Substances Against Aspergillus fumigatus in Clinical and Environmental Samples to Address Antimicrobial Resistance.
Journal: International journal of molecular sciences
Published: December 18, 2024
Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein.
Journal: Antibodies (Basel, Switzerland)
Published: November 15, 2023
Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer.
Journal: Frontiers in immunology
Published: February 01, 2023
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
Journal: Journal for immunotherapy of cancer
Published: October 27, 2021
VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens' Prediction.
Journal: Vaccines
Published: June 04, 2021
Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese.
Journal: Microbial ecology
Published: April 26, 2021
Correction: A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.
Journal: PLoS neglected tropical diseases
Published: April 13, 2021
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 06, 2020
Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing.
Journal: International journal of molecular sciences
Published: November 30, 2020
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Journal: Science translational medicine
Published: October 08, 2019
Last Updated: 09/26/2026